Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan

Nephrology

Volumn 24, Issue 9, 2019, Pages 904-911

  Ohara, Ken ^a   Masuda, Takahiro ^a   Murakami, Takuya ^a   Imai, Toshimi ^a   Yoshizawa, Hiromichi ^a   Nakagawa, Saki ^a   Okada, Mari ^a   Miki, Atsushi ^a   Myoga, Akihiro ^a   Sugase, Taro ^a   Sekiguchi, Chuji ^b   Miyazawa, Yasuharu ^b   Maeshima, Akito ^a   Akimoto, Tetsu ^a   Saito, Osamu ^a   Muto, Shigeaki ^a   Nagata, Daisuke ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Nasu Central Hospital   (Japan)

Author keywords

bioimpedance analysis; fluid distribution; natriuresis; osmotic diuretic; SGLT2 inhibition

Indexed keywords

ALBUMIN; BRAIN NATRIURETIC PEPTIDE; CHLORIDE; DAPAGLIFLOZIN; FUROSEMIDE; POTASSIUM; SODIUM; TOLVAPTAN; URIC ACID; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; LOOP DIURETIC AGENT; VASOPRESSIN RECEPTOR ANTAGONIST;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHLORIDE BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ESTIMATED GLOMERULAR FILTRATION RATE; EXTRACELLULAR FLUID; FEMALE; FLUID FLOW; FLUID RETENTION; HUMAN; MALE; OSMOTIC PRESSURE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SODIUM BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINE OSMOLALITY; URINE VOLUME; BODY COMPOSITION; COMPARATIVE STUDY; DRUG EFFECT; ELECTROLYTE BALANCE; FLUID SHIFT; METABOLIC DISORDER; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZHYDRYL COMPOUNDS; BODY COMPOSITION; FEMALE; FLUID SHIFTS; FUROSEMIDE; GLUCOSIDES; HUMANS; MALE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TIME FACTORS; TOLVAPTAN; TREATMENT OUTCOME; WATER-ELECTROLYTE BALANCE; WATER-ELECTROLYTE IMBALANCE;

EID: 85063944005     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.13552     Document Type: Article

References (30)

1. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition. Diabetologia 2017; 60: 215–25.
2. Ito M, Tanaka T. The anticipated Renoprotective effects of sodium-glucose Cotransporter 2 inhibitors. Intern. Med. 2018; 57: 2105–14.
3. Vallon V, Platt KA, Cunard R et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J. Am. Soc. Nephrol. 2011; 22: 104–12.
4. Rieg T, Masuda T, Gerasimova M et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am. J. Physiol. Renal Physiol. 2014; 306: F188–93.
5. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J. Clin. Invest. 1994; 93: 397–404.
6. Tanaka H, Takano K, Iijima H et al. Factors affecting Canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus. Adv. Ther. 2017; 34: 436–51.
7. Imai T, Akimoto T, Ito C, Masuda T, Nagata D. Management of Diabetes Associated with Nephrotic syndrome: Therapeutic potential of Dapagliflozin for protracted volume retention. Drug Target Insights. 2015; 9: 29–31.
8. Masuda T, Watanabe Y, Fukuda K et al. Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat. Am. J. Physiol. Renal Physiol. 2018; 315: F653–F64.
9. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab. 2013; 15: 853–62.
10. Masuda T, Ohara K, Murakami T et al. Sodium-glucose cotransporter 2 inhibition with Dapagliflozin ameliorates extracellular volume expansion in diabetic kidney disease patients. POJ Diabetes Obes. 2017; 1: 1–8.
11. Zoccali C, Moissl U, Chazot C et al. Chronic fluid overload and mortality in ESRD. J. Am. Soc. Nephrol. 2017; 28: 2491–7.
12. Hung SC, Lai YS, Kuo KL, Tarng DC. Volume overload and adverse outcomes in chronic kidney disease: Clinical observational and animal studies. J. Am. Heart Assoc. 2015; 4: e001918.
13. Takada T, Masaki T, Hoshiyama A, Toki T, Kamata Y, Shichiri M. Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide. Nephrology (Carlton) 2018; 23: 883–6.
14. Masuda T, Murakami T, Igarashi Y et al. Dual impact of Tolvaptan on intracellular and extracellular water in chronic kidney disease patients with fluid retention. Intern. Med. 2016; 55: 2759–64.
15. Costello-Boerrigter LC, Smith WB, Boerrigter G et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Renal Physiol. 2006; 290: F273–8.
16. Mori T, Oba I, Koizumi K et al. Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis. Adv Perit. Dial. 2013; 29: 33–7.
17. Matsuo S, Imai E, Horio M et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 2009; 53: 982–92.
18. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: A position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int. 2005; 67: 2089–100.
19. Mahon WA, Holland J, Urowitz MB. Hyperosmolar, non-ketotic diabetic coma. Can. Med. Assoc. J. 1968; 99: 1090–2.
20. Landis EM, Pappenheimer HJ. Exchange of substances through the capillary walls. In: Handbook of Physiology, Chapter 29. Washington D.C: American Physiology Society, 1965; 961–1034.
21. Sasaki N, Takeda S, Saito T, Ando Y, Kusano E. Analysis of metabolic syndrome and pulse wave velocity in hemodialysis patients: Diagnosis of obesity by bioelectrical impedance analysis and a novel risk factor for atherosclerosis. Nihon Jinzo Gakkai Shi. 2009; 51: 476–83.
22. InBody Co., Ltd. InBody S10 USER'S MANUAL 2012. Available from URL: http://inbody.in/wp-content/plugins/download-attachments/includes/download.php?id=6551. Accessed August 17, 2018.
23. Januzzi JL, Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 2013; 127: 500–8 discussion 08.
24. Goldsmith SR, Bart BA, Burnett J. Decongestive therapy and renal function in acute heart failure: Time for a new approach? Circ. Heart Fail. 2014; 7: 531–5.
25. Vasavada N, Agarwal R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int. 2003; 64: 1772–9.
26. Soderberg M, Hahn RG, Cederholm T. Bioelectric impedance analysis of acute body water changes in congestive heart failure. Scand. J. Clin. Lab. Invest. 2001; 61: 89–94.
27. Shoaf SE, Bricmont P, Mallikaarjun S. Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. Kidney Int. 2014; 85: 953–61.
28. McCafferty K, Fan S, Davenport A. Extracellular volume expansion, measured by multifrequency bioimpedance, does not help preserve residual renal function in peritoneal dialysis patients. Kidney Int. 2014; 85: 151–7.
29. Kim CR, Shin JH, Hwang JH, Kim SH. Monitoring volume status using bioelectrical impedance analysis in chronic hemodialysis patients. ASAIO J. 2018; 64: 245–52.
30. Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018; 94: 26–39.